PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease Reportshyperkalemia
MeSH D006947 - hyperkalemia
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D014883:Water-electrolyte imbalance
1 Company
1 Drug
$
Success rate
D006947: 
Hyperkalemia
2 Companies
2 Drugs
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
AstraZenecaSodium zirconium cyclosilicate Lokelma 2032-02-10 2018-05-18 $233 M Q2/21-Q2/24 
ViforPatiromer Veltassa  2017-07-19   
Clinical Trials
Historical Success Rate
Phase 1
25%
1/4
Phase 2
78%
7/9
Phase 3
58%
7/12
Approved: 5Overall Success rate: 11%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
AstraZeneca
Sodium zirconium cyclosilicate,
Angiotensin ii,
Benzocaine,
Aldosterone,
Aspartame,
Bevifimod,
Levoglucose,
Insulin,
Sodium polystyrene sulfonate,
Spirolactone,
Viaject,
Lcz696
Vifor
Patiromer,
Txa127,
Docusate,
Aldosterone,
Aspartame,
Corticorelin,
Microcrystalline cellulose,
Spirolactone
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use